Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Moodys
Express Scripts
Colorcon

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR GRANISETRON HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Granisetron Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003213 ↗ Drugs to Reduce the Side Effects of Chemotherapy Completed Swiss Group for Clinical Cancer Research Phase 3 1996-05-01 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy.
NCT00004219 ↗ Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status Simbec Research Phase 3 1969-12-31 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and vomiting. PURPOSE: Randomized phase III trial to compare the effectiveness of lerisetron with that of granisetron in preventing nausea and vomiting in men who are being treated with radiation therapy for stage I seminoma.
NCT00005024 ↗ Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease Unknown status National Cancer Institute (NCI) Phase 3 1969-12-31 RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo in preventing nausea and vomiting after chemotherapy in patients who have malignant disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Granisetron Hydrochloride

Condition Name

Condition Name for Granisetron Hydrochloride
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 12
Nausea 12
Vomiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Granisetron Hydrochloride
Intervention Trials
Vomiting 55
Nausea 47
Postoperative Nausea and Vomiting 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Granisetron Hydrochloride

Trials by Country

Trials by Country for Granisetron Hydrochloride
Location Trials
United States 110
China 17
Egypt 9
Canada 7
Korea, Republic of 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Granisetron Hydrochloride
Location Trials
Michigan 7
Illinois 7
California 6
Pennsylvania 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Granisetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Granisetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 18
Phase 3 26
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Granisetron Hydrochloride
Clinical Trial Phase Trials
Completed 70
Unknown status 13
Recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Granisetron Hydrochloride

Sponsor Name

Sponsor Name for Granisetron Hydrochloride
Sponsor Trials
Prostrakan Pharmaceuticals 9
National Cancer Institute (NCI) 8
Merck Sharp & Dohme Corp. 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Granisetron Hydrochloride
Sponsor Trials
Other 108
Industry 56
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Dow
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.